IN2012DN01254A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01254A
IN2012DN01254A IN1254DEN2012A IN2012DN01254A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A IN 1254DEN2012 A IN1254DEN2012 A IN 1254DEN2012A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A
Authority
IN
India
Prior art keywords
compounds
enteralor
ainfections
isozazole
substituents
Prior art date
Application number
Other languages
English (en)
Inventor
Yitsun Richard Kao
Dan Yang
Kwokyung Yuen
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of IN2012DN01254A publication Critical patent/IN2012DN01254A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN1254DEN2012 2009-08-05 2010-08-05 IN2012DN01254A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23143109P 2009-08-05 2009-08-05
PCT/CN2010/001187 WO2011015037A1 (en) 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using there of cross reference to related applications

Publications (1)

Publication Number Publication Date
IN2012DN01254A true IN2012DN01254A (enExample) 2015-05-15

Family

ID=43543887

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1254DEN2012 IN2012DN01254A (enExample) 2009-08-05 2010-08-05

Country Status (13)

Country Link
EP (1) EP2462138B1 (enExample)
JP (1) JP2013501008A (enExample)
KR (1) KR20120092567A (enExample)
CN (1) CN102596946B (enExample)
AU (1) AU2010281265A1 (enExample)
BR (1) BR112012002331A2 (enExample)
CA (1) CA2770140A1 (enExample)
IL (1) IL217745A0 (enExample)
IN (1) IN2012DN01254A (enExample)
MX (1) MX2012001504A (enExample)
RU (1) RU2012104214A (enExample)
SG (1) SG178106A1 (enExample)
WO (1) WO2011015037A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011147198A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
JP5902172B2 (ja) 2010-09-08 2016-04-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 広範囲のインフルエンザ抗ウイルス薬としての新規ピペラジン類似体
CA2812935A1 (en) * 2010-09-28 2012-04-05 Bristol-Myers Squibb Company Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20140011700A1 (en) * 2011-03-25 2014-01-09 Bristol-Myers Squibb Company Three-dimensional structure of h1n1 nucleoprotein in complex with antiviral compounds
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
CN102432555A (zh) * 2011-09-09 2012-05-02 中国科学院广州生物医药与健康研究院 1,2,3-三氮唑-4(5)羧酰胺类化合物及其应用
JP6189874B2 (ja) 2012-03-13 2017-08-30 レスピバート・リミテツド 新規製薬学的製剤
WO2013171334A1 (en) * 2012-05-18 2013-11-21 Vironova Ab Methanethione compounds having antiviral activity
US9676734B2 (en) 2012-05-18 2017-06-13 Vironova Influenza Ab Compounds and methods
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
JP6397912B2 (ja) * 2013-07-30 2018-09-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Rsv抗ウイルス化合物としての置換ピリジンピペラジニルアナログ
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
JP2020506192A (ja) * 2017-02-02 2020-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. インフルエンザウイルスを阻害するためのピペラジン誘導体
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CU20210002A7 (es) 2018-07-10 2021-08-06 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI765323B (zh) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 抗流感病毒化合物及其製備方法和用途
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ, インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117150A (ja) 1991-10-25 1993-05-14 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
KR200293242Y1 (ko) * 2002-04-18 2002-11-01 전이범 산소 절단기호스
DE10236564A1 (de) * 2002-08-08 2004-05-19 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von papaverinartigem Vasodilatator und pharmazeutische Zusammensetzung
SG164378A1 (en) * 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
JP2013501008A (ja) 2013-01-10
KR20120092567A (ko) 2012-08-21
EP2462138A1 (en) 2012-06-13
CN102596946B (zh) 2015-06-17
SG178106A1 (en) 2012-03-29
EP2462138A4 (en) 2013-01-23
EP2462138B1 (en) 2014-09-24
CA2770140A1 (en) 2011-02-10
AU2010281265A2 (en) 2012-04-05
WO2011015037A1 (en) 2011-02-10
MX2012001504A (es) 2012-06-01
BR112012002331A2 (pt) 2019-09-24
RU2012104214A (ru) 2013-09-10
AU2010281265A1 (en) 2012-03-22
IL217745A0 (en) 2012-03-29
CN102596946A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PE20160127A1 (es) COMPUESTO ACIDO (2S,3S)-3-((2-(5-FLUORO-1H-PIRROLO[2,3-B]PIRIDIN-3-IL)-5-FLUOROPIRIMIDIN-4-IL)AMINO)BICICLO[2.2.2]OCTANO-2-CARBOXILICO COMO INHIBIDOR DE LA REPLICACION DEL VIRUS DE LA GRIPE A H1N1, H2N2, H3N2 o H5N1
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
MX2013007104A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
IL321503A (en) Recombinant virus, composition comprising the same, and uses thereof
BR112015013463A8 (pt) Derivados de carboxamida indol como antagonistas do receptor de p2x7
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201190234A1 (ru) Новые амидные производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
RU2012124039A (ru) Лечение микробных инфекций
ECSP13013080A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
EA201370058A1 (ru) Средство против вируса гриппа b
EA201370057A1 (ru) Средство против вируса гриппа b
NZ755900A (en) Methods of treating influenza